History of lipid lowering therapy use among adults initiating treatment with proprotein convertase subtilisin/kexin type 9 antibody inhibitors in the United States, 2015-2019.

Challenge

The prior lipid-lowering therapy history of patients initiating PCSK9 inhibitors had not been characterized in a large US population, creating gaps in understanding the clinical context of PCSK9 inhibitor use.

Solution

Target RWE researchers characterized the history of lipid-lowering therapy use among adults initiating PCSK9 inhibitors, describing prior statin exposure, maximum tolerated doses, and evidence of statin intolerance in a real-world US commercial claims population.